News from abbvie inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY® (ubrogepant) as an Effective Treatment Option for Migraine Attacks

Aug 05, 2020, 08:00 ET AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY® (ubrogepant) as an Effective Treatment Option for Migraine Attacks

AbbVie today announced Serena Williams as the spokesperson for UBRELVY® to raise awareness of an effective acute treatment option for people living...

Dec 09, 2017, 08:00 ET IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the RESONATE™-2 study (PCYC-1115/1116),...

Aug 02, 2017, 13:07 ET U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- After Failure of One or More Lines of Systemic Therapy

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA®...

Feb 16, 2017, 11:41 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable May 15, 2017...

Sep 26, 2016, 07:00 ET AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S....

Mar 04, 2016, 12:45 ET IMBRUVICA® (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib)...

Feb 18, 2016, 11:05 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share. The cash dividend is payable May 16, 2016...

Jul 17, 2015, 08:01 ET C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational...

Jun 12, 2015, 09:00 ET AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data from studies of DUOPA® (carbidopa and levodopa) enteral ...

Jun 12, 2015, 02:30 ET Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with...

May 22, 2015, 08:00 ET AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

AbbVie (NYSE: ABBV) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of...

May 01, 2015, 04:59 ET AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire ...

Oct 15, 2014, 11:53 ET AbbVie Board Recommends Stockholders Vote Against Shire Transaction

Following Shire plc's ("Shire") waiver of the three-day notice period, AbbVie Inc. ("AbbVie") (NYSE: ABBV) announces today its Board of Directors'...

Jul 18, 2014, 06:17 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

AbbVie Inc. ("AbbVie") will hold an analyst and investor call in respect of the recommended combination of AbbVie with Shire plc today at 8am CDT/2pm ...

Jul 18, 2014, 06:14 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Dear AbbVie Colleagues, Today I am very pleased to announce that the boards of AbbVie and Shire have agreed to combine our two great companies. This...

Jul 18, 2014, 06:12 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

On July 18, 2014, AbbVie issued an infographic highlighting AbbVie and Shire's complementary fit and the benefits of the proposed combination. A copy ...

Jul 18, 2014, 06:10 ET Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

Summary The Boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire...

Jul 08, 2014, 07:50 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Following the announcement on June 25, 2014, where AbbVie outlined its strong strategic rationale and commitment regarding a combination with Shire,...

Jun 25, 2014, 08:45 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

As previously notified, AbbVie Inc. ("AbbVie") will hold an analyst and investor call in respect of the indicative merger proposal made to Shire plc, ...

Jun 25, 2014, 07:00 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Following its announcement on June 20, 2014, AbbVie is pleased to outline the compelling strategic rationale for, and background to, its proposal to...

Dec 12, 2013, 12:09 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.40 per share. The cash dividend is payable Feb. 14, 2014...

Dec 10, 2013, 08:00 ET AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with...

Nov 18, 2013, 04:12 ET AbbVie and North Chicago Public Schools Announce $350,000 Grant to Advance Math Education

AbbVie, one of the nation's largest biopharmaceutical companies, and the North Chicago public schools announce a $350,000 grant for math education....

Nov 14, 2013, 08:15 ET AbbVie to Present at Jefferies 2013 Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president,...

Oct 01, 2013, 10:00 ET AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting

AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the...